Previous 10 | Next 10 |
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of a premarket...
In a note, Morgan Stanley's David Lewis expects medical device companies to experience a rapid recovery over the next 6-12 months after an "acute impact" from effects of the COVID-19 pandemic (Q1 and probably Q2 are going to be ugly), adding that he does not see any significant liquidity iss...
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported that today the Company is filing seve...
The threat of declining earnings because of reduced economic activity caused by the spread of the coronavirus, Covid-19, has finally overtaken the unbridled optimism that's been fueled by seasonal tailwinds , a resolution of impeachment worries, and decreasing trade tensions. As a result, o...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Chief Execu...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will rel...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Chief Execu...
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that the German I...
Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (SNM) devices for the treatment of bladder and bowel dysfunction, today announced U.S. Food & Drug Administrati...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
2024-06-19 23:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 07:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...